259 related articles for article (PubMed ID: 38638442)
1. Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma.
Tacchetti P; Talarico M; Barbato S; Pantani L; Mancuso K; Rizzello I; Zamagni E; Cavo M
Expert Rev Anticancer Ther; 2024 Jun; 24(6):379-395. PubMed ID: 38798125
[TBL] [Abstract][Full Text] [Related]
2. Bispecific Antibodies and Autologous Chimeric Antigen Receptor T cell therapies for Treatment of Hematological Malignancies.
Al Hadidi S; Heslop HE; Brenner MK; Suzuki M
Mol Ther; 2024 May; ():. PubMed ID: 38822527
[TBL] [Abstract][Full Text] [Related]
3. Beyond Chemotherapy: Present and Future Perspectives in the Treatment of Lymphoproliferative Disorders.
Massaro F; Andreozzi F; Abrassart T; Castiaux J; Massa H; Rizzo O; Vercruyssen M
Biomedicines; 2024 Apr; 12(5):. PubMed ID: 38790939
[TBL] [Abstract][Full Text] [Related]
4. Cancer therapy with antibodies.
Paul S; Konig MF; Pardoll DM; Bettegowda C; Papadopoulos N; Wright KM; Gabelli SB; Ho M; van Elsas A; Zhou S
Nat Rev Cancer; 2024 Jun; 24(6):399-426. PubMed ID: 38740967
[TBL] [Abstract][Full Text] [Related]
5. The evolving landscape of antibody-drug conjugates in ovarian cancer: new drugs for a new era.
García-Illescas D; Mazzeo R; García-Durán C; Oaknin A
Curr Opin Obstet Gynecol; 2024 Apr; 36(2):104-111. PubMed ID: 38170620
[TBL] [Abstract][Full Text] [Related]
6. Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy.
Qin X; Ning W; Liu H; Liu X; Luo W; Xia N
Acta Pharm Sin B; 2024 Jun; 14(6):2361-2377. PubMed ID: 38828136
[TBL] [Abstract][Full Text] [Related]
7. Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today's treat-to-target era.
Zhang L; Tai YT; Ho MZG; Qiu L; Anderson KC
Exp Hematol Oncol; 2017; 6():20. PubMed ID: 28725493
[TBL] [Abstract][Full Text] [Related]
8. Relapse after glofitamab, a novel unmet medical need with high rates of CD20 loss.
Carlo-Stella C
Br J Haematol; 2024 May; ():. PubMed ID: 38813657
[TBL] [Abstract][Full Text] [Related]
9. Innovations and trends in antibody repertoire analysis.
Townsend DR; Towers DM; Lavinder JJ; Ippolito GC
Curr Opin Biotechnol; 2024 Apr; 86():103082. PubMed ID: 38428225
[TBL] [Abstract][Full Text] [Related]
10. The importance of a go-to-market strategy in the commercialisation of cellular immunotherapies.
Piñel-Neparidze C; Bickerstaffe H; Shah S; Versnel J
Drug Discov Today; 2024 May; 29(7):104028. PubMed ID: 38759949
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous targeting of B-cell malignancies and human immunodeficiency virus with bispecific chimeric antigen receptor T cells.
Urak R; Pahlavanneshan S; Gittins B; Nakamura R; Zaia JA; Baird JH; Clark MC; Forman SJ; Wang X
Haematologica; 2024 May; ():. PubMed ID: 38779743
[TBL] [Abstract][Full Text] [Related]
12. CD20-based Immunotherapy of B-cell Derived Hematologic Malignancies.
Shanehbandi D; Majidi J; Kazemi T; Baradaran B; Aghebati-Maleki L
Curr Cancer Drug Targets; 2017; 17(5):423-444. PubMed ID: 28067179
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal Antibodies, Bispecific Antibodies and Antibody-Drug Conjugates in Oncohematology.
Mihăilă RG
Recent Pat Anticancer Drug Discov; 2020; 15(4):272-292. PubMed ID: 32981510
[TBL] [Abstract][Full Text] [Related]
14. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
[TBL] [Abstract][Full Text] [Related]
15. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
Davis JA; Shockley A; Hashmi H
J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
[TBL] [Abstract][Full Text] [Related]
16. Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells.
Dabkowska A; Domka K; Firczuk M
Front Immunol; 2024; 15():1363102. PubMed ID: 38638442
[TBL] [Abstract][Full Text] [Related]
17. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
Hong Y; Nam SM; Moon A
Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
